Paper - WANFANG MED ONLINE

You Position: Home > Paper

IL-2不同注射途径对慢性乙型肝炎患者T细胞功能的影响

( views:0, downloads:0 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 3

DOI:: 10.3969/j.issn.1009-3079.2001.03.028

Key Word:: 肝炎,乙型/药物疗法;肝炎,乙型/免疫学;白细胞介素2/投药和剂量;T淋巴细胞/药物作用

Abstract： @@ 临床上应用白介素-2(IL-2)或IL-2/LAK细胞治疗病毒性肝炎已取得一定的疗效[1-8].而IL-2的给药方式大多为大剂量静脉输注,治疗时间较长,常产生一些毒副作用,且治疗费用昂贵我们采用低剂量rIL-2直接注射到慢性乙型肝炎患者淋巴结(iLN)中,并与肌内注射(im)和静脉内滴注(iv)比较,观察3种给药方式对患者的T细胞亚群、体外激活后增殖能力和杀伤活性的影响,以期探索一种简便、有效和经济的给药方式.

Reference

[1]杜清友,王福生,徐东平,等.新型免疫活性细胞CIK体外对肝癌细胞的杀伤[J].2000,(8).
[2]靖大道,邱德凯.乙型肝硬变患者外周血IL-2,IL-2R与肝功能的关系[J].1998,(10).
[3]张美稀,章晓鹰,金树根,等.肝病患者外周血CD28+T细胞亚群变化[J].2000,(12).
[4]张树林,刘敏,朱江,等.Th2优势应答与HBV慢性感染[J].1999,(6).
[5]何景华,窦淑兰,卢红月.IL-2的肌肉注射与药理作用的关系[J].1999,(3).
[6]闫振武,梁秀玲,马桂芹,等.乙肝特异性CTL治疗慢性乙型肝炎的研究[J].1998,(4).
[7]李灼亮,涂荫国,王宝奎,等.抗CD_3激活的自身杀伤细胞回输治疗慢性乙型肝炎近期疗效观察[J].1994,(2).
[8]王九平,朱勇.慢性乙型肝炎患者T细胞亚群,mIL-2R,sIL-2R,IL-6,IL-8,TNF …[J].2000,008 (7).
[9]张言超,吴文漪,陈明,等.慢性中重型肝炎自体LAK细胞回输治疗效果的细胞免疫分析[J].1998,(9).
[10]Young AJ.The physiology of lymphocyte migration through the single lymph node in vivo.[J].1999,11(2).
[11]M, Nishioka,H, Kagawa,M, Shirai,etc.Effects of human recombinant interleukin 2 in patients with chronic hepatitis B: a preliminary report.[J].1987,82.
[12]周岳进,许雪延,胡素琴,等.基因工程干扰素 α-2B 加CD_3AK治疗慢性乙型肝炎[J].1997,(4).
[13]李旭红,王崇国,庄岳鹏,等.特异性细胞毒T淋巴细胞对慢性乙肝疗效观察[J].1998,(5).
[14]姚宁,苏盛.自体LAK细胞回输疗法治疗慢性乙型肝炎的临床试验[J].1991,030 (1).
[15]陈复兴,刘军权,王涛,等.人PBMC经数种活化剂活化后的表型变化[J].1999,(3).
[16]RC Sn,V Makovska,S Moran,etc.The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2[J].1991,63(2).
[17]Issekutz TB,Kulidjian AA,Inman R.Rodent models of lymphocyte migration.[J].1999,11(2).
[18]陈复兴.病毒性疾病的T细胞免疫治疗[J].1997,(2).
[19]蒋道荣,姚登福,孟宪镛.乙型肝炎患者外周血T细胞亚群和可溶性IL-2R的研究[J].1997,(2).
[20]董寒梅,张端阳.自体与异体LAK细胞治疗慢性肝炎130例[J].1997,(5).
[21]刘军权.用乳酸脱氢酶试剂盒检测LAK细胞活性[J].1995,(2).
[22]Riddell, S. R.,Greenberg, P. D..Therapeutic Reconstitution of Human Viral Immunity by Adoptive Transfer of Cytotoxic T Lymphocyte Clones[J].1994,1(189).
[23]M A, Caligiuri,C, Murray,R J, Soiffer,etc.Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.[J].1991,9.
[24]南月敏,王麟士,吴文娟,等.乙型肝炎及原发性肝癌患者SIL-2R的变化[J].1997,(5).
[25]J, Bubeník,W, Den Otter,E, Huland.Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines.[J].2000,49(2).
[26]W, Den Otter,F W, Hill,W R, Klein,etc.Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up.[J].1995,41(1).
[27]Shinichi Kakumu,Akihiko Fuji,Kentaro Yoshioka,etc.Pilot study of recombinant human interleukin 2 for chronic type B hepatitis[J].1988,8(3).
[28]Riddell SR,Greenberg PD.Principles for adoptive T cell therapy of human viral diseases.[J].1995,13.
[29]黄自存,张国良.自身LAK细胞回输治疗慢性乙型肝炎[J].1992,(4).
[30]吕庶.自体TAK细胞回输治疗乙型肝炎[J].1998,(5).
[31]R A, Maas,H F, Dullens,W, Den Otter.Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.[J].1993,36(3).